Literature DB >> 10200283

A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3.

Y Wang1, M K Spatz, K Kannan, H Hayk, A Avivi, M Gorivodsky, M Pines, A Yayon, P Lonai, D Givol.   

Abstract

Achondroplasia, the most common form of dwarfism in man, is a dominant genetic disorder caused by a point mutation (G380R) in the transmembrane region of fibroblast growth factor receptor 3 (FGFR3). We used gene targeting to introduce the human achondroplasia mutation into the murine FGFR3 gene. Heterozygotes for this point mutation that carried the neo cassette were normal whereas neo+ homozygotes had a phenotype similar to FGFR3-deficient mice, exhibiting bone overgrowth. This was because of interference with mRNA processing in the presence of the neo cassette. Removal of the neo selection marker by Cre/loxP recombination yielded a dominant dwarf phenotype. These mice are distinguished by their small size, shortened craniofacial area, hypoplasia of the midface with protruding incisors, distorted brain case with anteriorly shifted foramen magnum, kyphosis, and narrowed and distorted growth plates in the long bones, vertebrae, and ribs. These experiments demonstrate that achondroplasia results from a gain-of-FGFR3-function leading to inhibition of chondrocyte proliferation. These achondroplastic dwarf mice represent a reliable and useful model for developing drugs for potential treatment of the human disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200283      PMCID: PMC16353          DOI: 10.1073/pnas.96.8.4455

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase.

Authors:  Y Lallemand; V Luria; R Haffner-Krausz; P Lonai
Journal:  Transgenic Res       Date:  1998-03       Impact factor: 2.788

Review 2.  Skeletal disorders associated with fibroblast growth factor receptor mutations.

Authors:  L De Moerlooze; C Dickson
Journal:  Curr Opin Genet Dev       Date:  1997-06       Impact factor: 5.578

Review 3.  FGFR activation in skeletal disorders: too much of a good thing.

Authors:  M K Webster; D J Donoghue
Journal:  Trends Genet       Date:  1997-05       Impact factor: 11.639

4.  Activation of FGF receptors by mutations in the transmembrane domain.

Authors:  Y Li; K Mangasarian; A Mansukhani; C Basilico
Journal:  Oncogene       Date:  1997-03-27       Impact factor: 9.867

Review 5.  Craniosynostosis: genes and mechanisms.

Authors:  A O Wilkie
Journal:  Hum Mol Genet       Date:  1997       Impact factor: 6.150

6.  Effects of fibroblast growth factor-2 on longitudinal bone growth.

Authors:  E E Mancilla; F De Luca; J A Uyeda; F S Czerwiec; J Baron
Journal:  Endocrinology       Date:  1998-06       Impact factor: 4.736

7.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.

Authors:  M C Naski; Q Wang; J Xu; D M Ornitz
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

8.  Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice.

Authors:  J D Coffin; R Z Florkiewicz; J Neumann; T Mort-Hopkins; G W Dorn; P Lightfoot; R German; P N Howles; A Kier; B A O'Toole
Journal:  Mol Biol Cell       Date:  1995-12       Impact factor: 4.138

9.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.

Authors:  M K Webster; D J Donoghue
Journal:  EMBO J       Date:  1996-02-01       Impact factor: 11.598

10.  Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.

Authors:  J S Colvin; B A Bohne; G W Harding; D G McEwen; D M Ornitz
Journal:  Nat Genet       Date:  1996-04       Impact factor: 38.330

View more
  59 in total

Review 1.  Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Authors:  William A Horton; Gregory P Lunstrum
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

2.  Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal.

Authors:  Arjun Sebastian; Takehiko Matsushita; Aya Kawanami; Susan Mackem; Gary E Landreth; Shunichi Murakami
Journal:  J Orthop Res       Date:  2010-10-04       Impact factor: 3.494

3.  Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway.

Authors:  S Murakami; M Kan; W L McKeehan; B de Crombrugghe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 4.  Molecular basis for skeletal variation: insights from developmental genetic studies in mice.

Authors:  C Kappen; A Neubüser; R Balling; R Finnell
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2007-12

5.  Perichondrial expression of Wdr5 regulates chondrocyte proliferation and differentiation.

Authors:  Francesca Gori; Eric D Zhu; Marie B Demay
Journal:  Dev Biol       Date:  2009-02-13       Impact factor: 3.582

Review 6.  A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation.

Authors:  Elena Kozhemyakina; Andrew B Lassar; Elazar Zelzer
Journal:  Development       Date:  2015-03-01       Impact factor: 6.868

7.  Increased sensitivity to agonist-induced seizures, straub tail, and hippocampal theta rhythm in knock-in mice carrying hypersensitive alpha 4 nicotinic receptors.

Authors:  Carlos Fonck; Raad Nashmi; Purnima Deshpande; M Imad Damaj; Michael J Marks; Anett Riedel; Johannes Schwarz; Allan C Collins; Cesar Labarca; Henry A Lester
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

8.  Kidney cysts, pancreatic cysts, and biliary disease in a mouse model of autosomal recessive polycystic kidney disease.

Authors:  Scott S Williams; Patricia Cobo-Stark; Leighton R James; Stefan Somlo; Peter Igarashi
Journal:  Pediatr Nephrol       Date:  2008-02-20       Impact factor: 3.714

9.  Neonatal lethality, dwarfism, and abnormal brain development in Dmbx1 mutant mice.

Authors:  Akihira Ohtoshi; Richard R Behringer
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  Hearing loss in a mouse model of Muenke syndrome.

Authors:  Suzanne L Mansour; Stephen R F Twigg; Rowena M Freeland; Steven A Wall; Chaoying Li; Andrew O M Wilkie
Journal:  Hum Mol Genet       Date:  2008-09-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.